E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Prospective cohort diagnostic test accuracy study in 30 breast cancer patients scheduled for neoadjuvant chemotherapy (15 of which with Pgp-positive and 15 with Pgp-negative tumors) and 10 low grade glioma patients (group G) scheduled for surgical tumor removal. |
|
E.1.1.1 | Medical condition in easily understood language |
breast cancer patients scheduled for neoadjuvant chemotherapy and low grade glioma patients (group G) scheduled for surgical tumor removal. |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10006153 |
E.1.2 | Term | Brain tumor |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10006192 |
E.1.2 | Term | Breast cancer NOS |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To correlate PET imaging outcome parameters (e.g. volume of distribution (VT) of [11C]tariquidar in tumor tissue) at staging with Pgp expression levels measured by IHC and/or at baseline (diagnostic biopsy) |
|
E.2.2 | Secondary objectives of the trial |
To correlate [11C]tariquidar PET imaging outcome parameters and Pgp expression levels at baseline with response to neoadjuvant chemotherapy measured by Response Evaluation Criteria In Solid Tumors (RECIST) Assess safety and tolerability of [11C]tariquidar PET imaging To correlate changes in [11C]tariquidar PET imaging outcome parameters with changes in Pgp expression levels before and after chemotherapy (optional) To correlate [11C]tariquidar PET imaging outcome parameters and Pgp expression levels measured after chemotherapy with response to neoadjuvant chemotherapy measured by RECIST criteria (optional)
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Sex: female (only group B), male and female (group G) • Age: >18years old • Breast cancer patients scheduled for neoadjuvant chemotherapy (group B) or low grade glioma patients (group G) scheduled for surgical tumor removal. • Histologically confirmed breast cancer with estimated lesion size of >2 cm (gor group B only) • Availability of tumor biopsy at the time of diagnosis for IHC and/or WB analysis • Volunteers must sign the informed consent prior to inclusion in the study • Ability to comprehend the full nature and purpose of the study, including possible risks and side effects
|
|
E.4 | Principal exclusion criteria |
Any abnormality found as part of the pretreatment screening or in any of the laboratory tests performed that the investigators considers might influence the outcome of the study (e.g. co-morbidities) • Participation in a clinical study with a radioactive substance in the last 12 months • Intake of any medication during two weeks before the start of the study, which the investigator considers may affect the validity of the study, due to interference with CYP3A4 and/or Pgp • For female subjects in child-bearing age: Pregnancy or breastfeeding
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Correlation of [11C]tariquidar PET imaging outcome parameters at staging with Pgp expression levels measured by IHC at baseline (diagnostic biopsy) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Correlation of [11C]tariquidar PET imaging outcome parameters and Pgp expression levels at baseline with response to neoadjuvant chemotherapy measured by RECIST criteria |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
after end of neoadjuvant chemotherapy (expected duration: 3 weeks) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Failure to observe the study conditions or instructions from the study team Failure to comply with any aspect to the protocol Detection of drugs or addictive substances Occurrence of AEs or inter-current diseases which the investigator deems to be unacceptable
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |